Literature DB >> 2454362

Acute hemodynamic effects of the vasodilating and beta-blocking agent carvedilol in comparison to propranolol.

T Wendt1, R van der Does, R Schräder, H Landgraf, G Kober.   

Abstract

In a randomized double-blind study, oral doses of 50 mg carvedilol were compared to 40 mg propranolol in 16 male patients with coronary heart disease (12 without significant stenosis after percutaneous transluminal coronary angioplasty) at rest, during and after exercise, and before and 80 min after drug application. Systemic and pulmonary pressures, heart rate, cardiac index, and lower limb blood flow were measured, and systemic and pulmonary resistances calculated. Carvedilol does not lead, as the classical beta-blocker propranolol does, to an increase in systemic or pulmonary resistance, nor to a decrease in cardiac output, or to an increase of the pulmonary capillary wedge pressure during exercise. In contrast to propranolol, the postexercise lower limb blood flow has increased significantly. The differences in action between the two beta-blockers can be explained by the vasodilating properties of carvedilol. Due to these acute effects, carvedilol may be of advantage compared to propranolol in the treatment of peripheral occlusive artery disease, hypertension, and coronary vasospasm.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2454362

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

Review 1.  The vasodilatory beta-blockers.

Authors:  Michala E Pedersen; John R Cockcroft
Journal:  Curr Hypertens Rep       Date:  2007-08       Impact factor: 5.369

Review 2.  Neurohormonal modulation as therapeutic avenue for right ventricular dysfunction in pulmonary artery hypertension: till the dawn, waiting.

Authors:  Roy Emanuel; Astha Chichra; Nirav Patel; Thierry H Le Jemtel; Abhishek Jaiswal
Journal:  Ann Transl Med       Date:  2018-08

Review 3.  Progress in antihypertensive therapy with a multiple-action drug.

Authors:  B N Prichard; B Tomlinson
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 4.  Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  C J Dunn; A P Lea; A J Wagstaff
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 5.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

6.  Clinical pharmacology of carvedilol.

Authors:  B Tomlinson; B N Prichard; B R Graham; R J Walden
Journal:  Clin Investig       Date:  1992

Review 7.  Clinical pharmacokinetics and pharmacodynamics of carvedilol.

Authors:  T Morgan
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

8.  Pharmacological characteristics of the stereoisomers of carvedilol.

Authors:  W Bartsch; G Sponer; K Strein; B Müller-Beckmann; L Kling; E Böhm; U Martin; H O Borbe
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

9.  Influence of carvedilol and propranolol on coronary blood flow.

Authors:  H Sievert; G Frey; R Schräder; T Schmidt; R van der Does; M Kaltenbach; G Kober
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 10.  Hemodynamic profile of carvedilol.

Authors:  V Hombach; M Kochs; M Höher; T Eggeling; W Haerer; S Wieshammer; A Schmidt
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.